Posted by Michael Wonder on 30 Sep 2024
FDA approves imaging drug for evaluation of myocardial ischaemia and infarction
27 September 2024 - The US FDA has approved Flyrcado (flurpiridaz F 18) in adult patients with known or suspected coronary artery disease to evaluate for myocardial ischaemia and infarction.
Flyrcado is a cyclotron produced radioactive diagnostic drug for positron emission tomography myocardial perfusion imaging under rest or stress (pharmacologic or exercise).
